This page shows the latest Zalviso news and features for those working in and with pharma, biotech and healthcare.
Zalviso is a non-invasive, handheld system that allows hospital patients to self-dose with sublingual sufenatil microtablets. ... delivery. AcelRx developed Zalviso and entered into a commercial collaboration with Grunenthal at the end of 2013.
Grunenthal's Zalviso (sufentanil) for the treatment of post-operative pain. A hybrid medicine, Zalviso's application relied in part on the results of studies carried out with a reference product
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
It is our passion to help these patients.”. It is also investing in New Technical Entities (NTEs) which include new formulations and devices, acquiring Zalviso, a combination of a medical device
PDL BioPharma is buying out the majority of the expected royalty stream from EU sales of AcelRX's phase III product, Zalviso for $65m. ... Royalty monetisation. 110. AcelRx Pharmaceuticals. PDL BioPharma. Zalviso sub-lingual formulation of sufentanil.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...